Darius Lakdawalla, PhD

The prices of targeted oncology therapies have grown substantially, but revenues have not. This is due in part to large declines in per-drug patient counts.

Geographic variation in cancer treatment spending reveals that chemotherapy and hospital inpatient care may offer opportunities for savings for practices participating in the Oncology Care Model.

This study found that brand price at launch and generic entry overstates long-run average pharmaceutical costs, with and without accounting for medical cost offsets.

This study demonstrates that common pharmacy claims-based measures underestimate the effect of actual adherence on inpatient costs among patients with serious mental illness.

Availability of multiple sclerosis (MS) therapies provides substantial value to the currently healthy (who may contract MS in the future), particularly when treatment is fully covered by insurance.

This study examined the impact of prior authorization formularies on the likelihood that patients with schizophrenia will be arrested and incarcerated.

Darius Lakdawalla, PhD, addresses the value of diabetes patients' adherence in this clip.

Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.